Drug Shortage Report for APO-DABIGATRAN
| Report ID | 87509 |
| Drug Identification Number | 02468905 |
| Brand name | APO-DABIGATRAN |
| Common or Proper name | DABIGATRAN |
| Company Name | APOTEX INC |
| Market Status | MARKETED |
| Active Ingredient(s) | DABIGATRAN ETEXILATE |
| Strength(s) | 110MG |
| Dosage form(s) | CAPSULE |
| Route of administration | ORAL |
| Packaging size | 60 BTL |
| ATC code | B01AE |
| ATC description | ANTITHROMBOTIC AGENTS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2019-06-24 |
| Estimated end date | Unknown |
| Actual end date | 2022-10-06 |
| Shortage status | Resolved |
| Updated date | 2022-10-07 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 150 SIGNET DRIVE TORONTO, ONTARIO CANADA M9L 1T9 |
| Company contact information | Apotex Customer Service - 1-877-427-6839 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v5 | 2022-10-07 | English | Compare |
| v4 | 2022-10-06 | French | Compare |
| v3 | 2022-10-06 | English | Compare |
| v2 | 2019-06-26 | French | Compare |
| v1 | 2019-06-26 | English | Compare |
Showing 1 to 5 of 5